Moderna Announces Phase 3 of its COVID-19 Vaccine is 94.5% Effective

In another promising medical development, the biotechnology company Moderna has announced its COVID-19 vaccine could be up to 94.5% effective.

The news comes a week after Pfizer announced its vaccine could be up to 90% effective based on a similar, early analysis from its Phase 3 trial.

In a release Monday, Moderna said its Phase 3 trial “met statistical criteria with a vaccine efficacy of 94.5%,” according to an early analysis of the data that included 95 participants with confirmed cases of COVID-19.

Read the source article at abcnews.go.com

Leave a Review or Comment

Back to top button